C4 Therapeutics, Inc. (CCCC)
NASDAQ: CCCC · Real-Time Price · USD
3.510
+0.110 (3.24%)
At close: Sep 11, 2026, 4:00 PM EDT
3.500
-0.010 (-0.28%)
After-hours: Sep 11, 2026, 7:30 PM EDT
C4 Therapeutics Revenue
C4 Therapeutics had revenue of $6.64M in the quarter ending June 30, 2026, with 2.75% growth. This brings the company's revenue in the last twelve months to $35.04M, up 2.33% year-over-year. In the year 2025, C4 Therapeutics had annual revenue of $35.95M with 1.02% growth.
Revenue (ttm)
$35.04M
Revenue Growth
+2.33%
P/S Ratio
12.32
Revenue / Employee
$336,913
Employees
104
Market Cap
431.82M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 35.95M | 363.00K | 1.02% |
| Dec 31, 2024 | 35.58M | 4.49M | 14.43% |
| Dec 31, 2022 | 31.10M | -14.69M | -32.08% |
| Dec 31, 2021 | 45.79M | 12.59M | 37.93% |
| Dec 31, 2020 | 33.20M | 11.81M | 55.25% |
| Dec 31, 2019 | 21.38M | 2.02M | 10.42% |
| Dec 31, 2018 | 19.36M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
CCCC News
- 3 days ago - C4 Therapeutics Transcript: Wells Fargo 21st Annual Healthcare Conference - Transcripts
- 10 days ago - C4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple Myeloma Trial at the 23rd International Myeloma Society (IMS) Annual Meeting - GlobeNewsWire
- 4 weeks ago - C4 Therapeutics reports Q2 EPS (18c), consensus (23c) - TheFly
- 4 weeks ago - C4 Therapeutics Earnings release: Q2 2026 - Filings
- 4 weeks ago - C4 Therapeutics Quarterly report: Q2 2026 - Filings
- 4 weeks ago - C4 Therapeutics Slides: Corporate presentation - Filings
- 2 months ago - C4 Therapeutics Transcript: AGM 2026 - Transcripts
- 2 months ago - C4 Therapeutics Transcript: KOL event - Transcripts